Sevabertinib is an oral, reversible, small-molecule tyrosine kinase inhibitor (TKI) designed to target HER2-activating ...
Novo Nordisk has raised its full-year 2026 outlook for adjusted sales and operating profit following a stronger-than-expected ...
Alembic Pharmaceuticals Limited reported a massive 81% year-on-year surge in consolidated profit after tax (PAT) to Rs. 335 ...
Updated Phase 1 TRIgnite-1 data includes longer follow-up and early dose-expansion results for heavily pretreated multiple ...
The expanded collaboration combines DifGen’s development and US manufacturing capabilities with Alembic’s established US ...
Bright Minds Biosciences has suffered a regulatory setback after the US Food and Drug Administration (FDA) placed a partial ...
BASF is stepping up its push into next-generation beauty and skincare innovation with the launch of Lincare, a naturally ...
International operations emerged as the biggest growth driver, posting a 34.5% increase in revenue to Rs 16,652 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results